A cumulative DVH shows the volume of a contoured structure receiving at least a specified dose, whereas a differential DVH shows the volume receiving doses within defined ranges. The cumulative form supports direct assessment of how much target or normal-tissue volume exceeds dose levels, while the differential form displays the distribution of dose across those ranges.
Sorting the calculated dose for every voxel within a contoured structure converts a complex three-dimensional dose distribution into a volume-based summary. This makes it possible to determine how much of the tumor or normal tissue receives particular dose levels. The resulting curve supports consistent comparison of dose distribution among structures and between treatment plans.
Dose Volume Histogram metrics help evaluate target coverage, dose conformity, and exposure of organs at risk. Target coverage indicates whether the contoured tumor receives the intended distribution, while conformity describes how appropriately dose is shaped around the target. Organ-at-risk exposure highlights normal tissues that may receive radiation, supporting assessment of treatment quality.
DVH findings make the trade-off between delivering radiation to the tumor and limiting dose to normal tissue more explicit. A plan may provide strong target coverage while exposing an organ at risk to greater dose, or reduce normal-tissue exposure while changing target dose distribution. Clinicians use these competing outcomes to judge and refine plan quality.
The workflow begins with contoured tumor and normal-tissue structures and a calculated dose distribution. Dose values are collected for each voxel within each structure, sorted, and displayed as cumulative or differential curves. Clinicians then inspect relevant metrics for coverage, conformity, and organ-at-risk exposure, using the findings to compare plans or guide adjustments.
Clinicians compare DVH results when judging alternative treatment plans or deciding whether a plan requires adjustment. The comparison can show whether one plan improves target coverage or conformity while increasing organ-at-risk exposure, or whether another reduces normal-tissue dose with an altered target distribution. This supports structured treatment-quality assessment in medicine.